The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Able to provide written consent
* Groups 1-3:
* Must undergo p16 staining on biopsy for enrollment
* Patients with \< 70% of tumor cells positive for p16 will be considered p16 negative
* Must undergo HPV16 family in situ hybridization (ISH) and/or RNA on biopsy or surgical specimen, unless amount of tissue is too small to have conclusive HPV ISH testing done on it
* Willingness and intent to return in person to enrolling institution for follow-up (during the Active Monitoring Phase of the study) for at least 2 of the standard follow-up time points for a total of 3 time-points including pre-treatment. A participant who does not return in person to Mayo Clinic Rochester for every standard of care post-treatment follow up will not be considered deviating from the protocol
* Group 4:
* Clinical suspicion or histopathologic diagnosis of head and neck cancer or neoplasm
* Primary salivary neoplasm
* Primary thyroid neoplasm
* Primary head and neck neoplasm
* Multi-cancer early detection (MCED) testing concerning for cancer
* Patient has given permission to give his/her tumor/tissue/blood/saliva sample for research testing
* Ability to complete questionnaire(s) by themselves or with assistance
* Primary language: English, Spanish, Arabic
Exclusion Criteria:
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
* Groups 1-3:
* Other active malignancy ≤ 5…